NASDAQ:IRON Disc Medicine Q1 2026 Earnings Report $70.91 +0.12 (+0.17%) Closing price 03:59 PM EasternExtended Trading$70.82 -0.09 (-0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Disc Medicine EPS ResultsActual EPS-$1.65Consensus EPS -$1.62Beat/MissMissed by -$0.03One Year Ago EPSN/ADisc Medicine Revenue ResultsActual RevenueN/AExpected Revenue$0.44 millionBeat/MissN/AYoY Revenue GrowthN/ADisc Medicine Announcement DetailsQuarterQ1 2026Date5/5/2026TimeBefore Market OpensConference Call DateTuesday, May 5, 2026Conference Call Time7:00AM ETUpcoming EarningsDisc Medicine's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Disc Medicine Earnings HeadlinesDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 21 at 1:09 PM | globenewswire.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONJune 19 at 2:07 PM | prnewswire.comBofA: Digital Dollar Coming 2025-2030The US government has ONLY ONE mathematical escape from $38.4T in debt: explosive AI-driven GDP growth. AI at scale (billions of autonomous machines transacting every second) can't run on Visa or ACH… It can't run on a banking system that closes at 5 PM… AI needs new financial infrastructure. June 23rd at 11 am ET, I'm revealing the exact convergence between America's debt crisis, AI infrastructure, and the ONE asset class the U.S. government has no choice but to fuel as trillions pour in.June 22 at 1:00 AM | Decentralized Masters (Ad)Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 18, 2026 | globenewswire.comDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsJune 15, 2026 | globenewswire.comDisc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook TranscriptJune 15, 2026 | seekingalpha.comSee More Disc Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email. Email Address About Disc MedicineDisc Medicine (NASDAQ:IRON) (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options. The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins. Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.View Disc Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Buy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They?Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?3 Oil Refiners Built to Cash In on Higher Crack SpreadsSatellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
